Article (Scientific journals)
Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial
Bruyère, Olivier; Dardenne, Nadia; Donneau, Anne-Françoise et al.
2020In Advances in Therapy, 37 (11), p. 4641-4648
Peer Reviewed verified by ORBi
 

Files


Full Text
Responder Profile to pharmaceutical-grade chondroitin sulfate. An analysis of the CONCEPT Trial.pdf
Publisher postprint (337.16 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
chondroitin sulfate; osteoarthritis; pain; responders; treatment
Abstract :
[en] Introduction: The recent CONCEPT study showed that 800 mg/day of pharmaceuticalgrade chondroitin sulfate (CS) was superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in patients with symptomatic knee osteoarthritis (OA). We investigate, in the present study, whether a responder profile to CS could be defined (i.e., to determine a patient’s profile with the best response to treatment). Methods: Subjects from the CS group of the CONCEPT study were included in the present analysis. Within the CS group, various subgroups were created on the basis of different categories of age, sex, body mass index, Kellgren and Lawrence grade, age since the beginning of OA, and baseline level of pain (i.e., VAS) or function (i.e., Lequesne index). The nonparametric Kruskal–Wallis (KW) test was applied to compare the VAS pain/Lequesne index evolutions between the subgroups, and the Dwass, Steel, Critchlow, Fligner (DSCF) procedure was used to compute multiple comparisons. The impact of various covariates on the VAS pain/Lequesne index evolution was assessed by means of multiple regression. Results: Across all analyses, the probability of response to CS treatment was significantly associated with the duration between the date of diagnosis and the initiation of treatment. In other words, the shorter the interval between the diagnosis and the beginning of the treatment, the higher the response for both pain and function, particularly for patients with a duration of less than 5 years compared to patients with a duration of 10 years or more. No other criteria were found to be consistently associated with the response to CS treatment. Conclusion: The treatment of OA with CS has the highest chance of success if administered in the early stage of the disease. Further research with other clinical outcomes should be carried out prior to widespread application of these findings. Trial Registration: ClinicalTrials.gov identifier, NCT03200288.
Disciplines :
General & internal medicine
Public health, health care sciences & services
Author, co-author :
Bruyère, Olivier  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Dardenne, Nadia  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Biostatistique
Donneau, Anne-Françoise ;  Université de Liège - ULiège > Département des sciences de la santé publique > Biostatistique
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial
Publication date :
2020
Journal title :
Advances in Therapy
ISSN :
0741-238X
eISSN :
1865-8652
Publisher :
Springer, New York, United States - New York
Volume :
37
Issue :
11
Pages :
4641-4648
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 28 October 2020

Statistics


Number of views
60 (4 by ULiège)
Number of downloads
36 (2 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
1
OpenCitations
 
2

Bibliography


Similar publications



Contact ORBi